License to the Program Sample Clauses

License to the Program. SA hereby grants to HP, under SA's intellectual property rights, a non-exclusive, worldwide license to use, reproduce, display, distribute, import and disclose the Program in object code format only for use in conjunction with an HP Printer. Such use limitation will also apply in the case of Enhancements for distribution to customers for support and maintenance purposes. Such license will include the right of HP to sublicense distributors, resellers, and other third parties to achieve the foregoing, and distribute the Program and/or Enhancements through any method HP deems appropriate, including but not limited to electronically through HP websites.
Sample 1Sample 2
AutoNDA by SimpleDocs
License to the Program. Licensor hereby grants to HP, under Licensor's intellectual property rights, a non-exclusive, worldwide license to use, reproduce, display, distribute, import and disclose the Program in object code format for use in conjunction with an HP Product. Such use limitation will not apply in the case of Enhancements for distribution to customers for support and maintenance purposes. Such license will include the right of HP to sublicense distributors, resellers, and other third parties to achieve the foregoing.
Sample 1
License to the Program. ClearCommerce hereby grants to HP, under ---------------------- ClearCommerce's intellectual property rights, [*] license to [*] [*] Certain information on this page has been omitted and filed separately with the Commission. Confidential treatment has been requested with respect to the omitted portions. [*]. Such use limitation will not apply in the case of [*] for distribution to customers for [*] purposes. Such license will include the right of HP to continue distributing Program versions that are first distributed by HP and subsequently updated or upgraded to a new release during the Term of the Agreement. Such license will include the right of HP [*]. ClearCommerce warrants that HP's distribution rights are [*] and shall use its [*] to ensure that ClearCommerce's existing or subsequent third party distribution arrangements do not infringe HP's distribution rights.
Sample 1Sample 2
License to the Program. ClearCommerce hereby grants to HP, under ---------------------- ClearCommerce's intellectual property rights, a non-exclusive, worldwide license to use, reproduce, display, distribute, import and disclose the Program in object code format for use either as a standalone product, or in conjunction with an HP Product, or to integrate and distribute with HP Products or other third party products. Such use limitation will not apply in the case of Enhancements for distribution to customers for support and maintenance purposes. Such license will include the right of HP to continue distributing Program versions that are first distributed by HP and subsequently updated or upgraded to a new release during the Term of the Agreement. Such license will include the right of HP to sublicense distributors, resellers, and other third parties to achieve the foregoing. ClearCommerce warrants that HP's distribution rights are worldwide and shall use its best efforts to ensure that ClearCommerce's existing or subsequent third party distribution arrangements do not infringe HP's distribution rights.
Sample 1Sample 2
License to the Program. Subject to the terms and conditions set forth herein, Licensor hereby grants to HP, its subsidiaries, divisions and affiliates a non-exclusive, worldwide license to use, reproduce, display, and distribute the Program in object code format and as bundled with a HP Product. Such license shall include the right of HP to sublicense distributors, resellers, and other third parties to achieve the foregoing. This license shall only permit HP to use, reproduce, display and distribute the Programs as an indivisible and inseparable whole, and therefore, unless expressly authorized in this license or an applicable SOW, HP is not authorized to use, reproduce, display or distribute only a part of a Program. All HP Products will be licensed to end users pursuant to the HP Software License Terms, the current form of which is attached hereto as EXHIBIT B.
Sample 1
License to the Program. Subject to Section 6.4.3, Licensor hereby grants and agrees to grant to Hewlett-Packard Company, under all intellectual property rights embodied in each Program, a non-exclusive, worldwide license to use, reproduce, display and distribute, without right of modification (except as set forth in Section 3.9), import, and disclose, the Program for use solely with the HP Product. Such license will include the right of HP to sublicense HP Subsidiaries, divisions, and affiliates, distributors, resellers, OEM’s, and other third parties (collectively, “Distributors”) to achieve the foregoing. Such copies of the Program will be distributed to customers and Distributors in accordance with an HP License and, if applicable, the software license terms applicable to any open source and/or freeware. HP acknowledges that installation of the Programs on the HP Product may involve a license key that restricts use of the Programs to a particular HP system identified by a unique system number. These system numbers will also be provided by HP on royalty reports. HP further acknowledges that the Programs may require activation on initial installation of the Programs and from time to time based on events and changes to the HP Product on which the Program is installed. Licensor will ensure that HP is enabled to generate any keys or other materials necessary for HP, its Customers, and partners to use the Programs to the extent of HP’s licenses hereunder. In the event HP establishes its own license key program, Licensor agrees to replace its current license key fulfillment system, subject to execution by the parties of a mutually acceptable Project Statement pursuant to Section 2.1. For avoidance of doubt, any termination or interruption of use of the Programs will be controlled solely by HP. Distribution of a Program by HP under this Agreement may be on media selected by HP, including magnetic or optical media or a web-based distribution method provided such Program is subject to the HP License.
Sample 1
License to the Program. S-A hereby grants to HP, under S-A's intellectual property rights, a non-exclusive, worldwide license to use, reproduce, display, distribute, import and disclose the Program in object code format only for use in conjunction with an HP Printer. Such use limitation will also apply in the case of Enhancements for distribution to customers for support and maintenance purposes. Such license will include the right of HP to sublicense distributors, resellers, and other third parties to achieve the foregoing, and distribute the Program and/or Enhancements through any method HP deems appropriate, including but not limited to electronically through HP websites.
Sample 1
AutoNDA by SimpleDocs
License to the Program. Subject to the terms and conditions set forth herein, Licensor hereby grants to Licensee, its subsidiaries, divisions and affiliates an exclusive, worldwide license to use, reproduce, display, and distribute in CD or digital distribution form the Program in object code format and/or as bundled with a Licensee Product, if applicable and upon prior written approval of Licensor. Such license shall include the right of Licensee to sublicense distributors, resellers, and other third parties to achieve the foregoing. This license shall only permit Licensee to use, reproduce, display and distribute the Programs as an indivisible and inseparable whole, and therefore, unless expressly authorized in this license or an applicable SOW, Licensee is not authorized to use, reproduce, display or distribute only a part of a Program. All Licensee Products will be licensed to end users pursuant to the Licensee Software License Terms, the current form of which is attached hereto as EXHIBIT C.
Sample 1
License to the Program 
Sample 1

Related to License to the Program

  • Conduct of Research Program Each Party:

  • Development Program A. Development activities to be undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization License Subject to the terms of this Agreement, including without limitation Section 2.2 and Theravance's Co-Promotion rights in Section 5.3.2, Theravance hereby grants to GSK, and GSK accepts, an exclusive license under the Theravance Patents and Theravance Know-How to make, have made, use, sell, offer for sale and import Alliance Products in the Territory.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Manufacturing and Supply Genentech shall be responsible for manufacturing and supplying Licensed Products for clinical use and commercial sale in the Genentech Field.

  • Commercialization Diligence Novartis shall dedicate commercially reasonable efforts, during each [**] month period, necessary to commercialize a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries. If Novartis commercializes a Licensed Product for a Profile, after receipt of Regulatory Approval therefor, in any of the U.S., Japan or the EU Major Market Countries, Novartis will be deemed to satisfy all diligence obligations with respect to such Profile.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development and Commercialization Subject to Sections 4.6 and 4.7, Fibrocell shall be solely responsible for the development and Commercialization of Fibrocell Products and Improved Products. Fibrocell shall be responsible for all costs incurred in connection with the Fibroblast Program except that Intrexon shall be responsible for the following: (a) costs of establishing manufacturing capabilities and facilities in connection with Intrexon’s manufacturing obligation under Section 4.6 (provided, however, that Intrexon may include an allocable portion of such costs, through depreciation and amortization, when calculating the Fully Loaded Cost of manufacturing a Fibrocell Product, to the extent such allocation, depreciation, and amortization is permitted by US GAAP, it being recognized that the majority of non-facilities scale-up costs cannot be capitalized and amortized under US GAAP); (b) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials (i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for the development of a Fibrocell Product or an Improved Product (which research costs shall be reimbursed by Fibrocell); (c) [*****]; and (d) costs of filing, prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of Intrexon Materials and related active pharmaceutical ingredients for clinical trials and Commercialization of Fibrocell Products undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally or through Third Party contractors retained by either Intrexon or Fibrocell (with Intrexon’s consent).

Time is Money Join Law Insider Premium to draft better contracts faster.